270 related articles for article (PubMed ID: 28254787)
1. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
[TBL] [Abstract][Full Text] [Related]
2. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
3. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Alatrash G; Perakis AA; Kerros C; Peters HL; Sukhumalchandra P; Zhang M; Jakher H; Zope M; Patenia R; Sergeeva A; Yi S; Young KH; Philips AV; Cernosek AM; Garber HR; Qiao N; Weng J; St John LS; Lu S; Clise-Dwyer K; Mittendorf EA; Ma Q; Molldrem JJ
Clin Cancer Res; 2018 Jul; 24(14):3386-3396. PubMed ID: 29661776
[No Abstract] [Full Text] [Related]
5. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
6. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.
Shetty V; Sinnathamby G; Nickens Z; Shah P; Hafner J; Mariello L; Kamal S; Vlahović G; Lyerly HK; Morse MA; Philip R
J Proteomics; 2011 May; 74(5):728-43. PubMed ID: 21362506
[TBL] [Abstract][Full Text] [Related]
7. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
8. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
9. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
11. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.
Chawla A; Alatrash G; Philips AV; Qiao N; Sukhumalchandra P; Kerros C; Diaconu I; Gall V; Neal S; Peters HL; Clise-Dwyer K; Molldrem JJ; Mittendorf EA
Cancer Immunol Immunother; 2016 Jun; 65(6):741-51. PubMed ID: 27129972
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
[TBL] [Abstract][Full Text] [Related]
14. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival.
Karanikas V; Colau D; Baurain JF; Chiari R; Thonnard J; Gutierrez-Roelens I; Goffinet C; Van Schaftingen EV; Weynants P; Boon T; Coulie PG
Cancer Res; 2001 May; 61(9):3718-24. PubMed ID: 11325844
[TBL] [Abstract][Full Text] [Related]
15. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
Alatrash G; Mittendorf EA; Sergeeva A; Sukhumalchandra P; Qiao N; Zhang M; St John LS; Ruisaard K; Haugen CE; Al-Atrache Z; Jakher H; Philips AV; Ding X; Chen JQ; Wu Y; Patenia RS; Bernatchez C; Vence LM; Radvanyi LG; Hwu P; Clise-Dwyer K; Ma Q; Lu S; Molldrem JJ
J Immunol; 2012 Dec; 189(11):5476-84. PubMed ID: 23105141
[TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibody with T-cell-like specificity recognizes MHC class I self-peptide presented by HLA-DR1 on activated cells.
Wölpl A; Halder T; Kalbacher H; Neumeyer H; Siemoneit K; Goldmann SF; Eiermann TH
Tissue Antigens; 1998 Mar; 51(3):258-69. PubMed ID: 9550326
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
18. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
19. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
